Dry Eye Disease: Consideration for Women's Health
- PMID: 30694724
- PMCID: PMC6482917
- DOI: 10.1089/jwh.2018.7041
Dry Eye Disease: Consideration for Women's Health
Abstract
Dry eye disease (DED) is a multifactorial disorder of the ocular surface and tear homeostasis that can result in discomfort, pain, and visual disturbance. Untreated, DED can become chronic, progressive, and significantly affect an individual's quality of life. Women are disproportionately affected by DED, are diagnosed at a younger age, and experience more severe symptoms compared with men. DED is associated with a wide range of comorbid conditions; there is a strong association between DED and autoimmune disorders, especially those that affect women at many times the rate of men. Treatment response questionnaires indicate women respond better to a wellness model of treatment for DED than men. Furthermore, women's health care-seeking behaviors provide opportunities for general practitioners, specialists, and women's health centers to help identify women with DED or at risk for DED for referral to an eye care specialist. This review of the prevalence of DED in women, and gender and sex-specific aspects of DED, highlight a significant opportunity for action. Earlier diagnosis and treatment of this common but burdensome condition could significantly improve a woman's quality of life.
Keywords: autoimmune disease; chronic; comorbid conditions; dry eye disease; epidemiology; postmenopausal women; primary care; progressive; quality of life.
Conflict of interest statement
C.M.—Consultant to Alcon, Allergan, Bausch and Lomb, Bruder, Checked-Up, i-Optics, Johnson & Johnson, Lenstec, Marco, Ocular Therapeutix, Inc., Omeros, PRN, Progressive Tech Training, Shire, SUN, TearLab, and Zeiss; M.M.—Consultant to Alcon, Allergan, Bausch and Lomb, Bruder, Johnson and Johnson, Sun, Shire, Omeros, TearLab, BioSyntrix, OCUSOFT, ORCA Surgical, BlephEx, BioTissue, and OCULUS USA; P.K.G.—Consultant to Alcon, Allergan, Aurea, BioTissue, Johnson & Johnson, Kala, NovaBay, Novartis, Ocular Science, Shire, TearLab, TearScience, and Zeiss; S.M.—Alcon, Allergan, INNOVA Medical Ophthalmics, Novartis, Optos, and Shire; K.K.N.—Consultant for Alcon, Allergan, Bausch and Lomb, Bruder, Hovione, ScienceBased Health, Shire/SarCode, SightSciences, and SUN/Insite. Research support: Alcon, Allergan, Bruder, Johnson & Johnson, Kala, National Institutes of Health, Oculus, Shire, and TearScience; K.D.—Consultant for Alcon, Allergan, Bausch and Lomb, Johnson & Johnson, NovaBay, Omeros, Shire, SUN, and TearLab.
Figures
References
-
- Craig JP, Nichols KK, Akpek EK, et al. . TFOS DEWS II Definition and Classification Report. Ocul Surf 2017;15:276–283 - PubMed
-
- Herrero-Vanrell R, Peral A. [International Dry Eye Workshop (DEWS). Update of the disease]. Arch Soc Esp Oftalmol 2007;82:733–734 - PubMed
-
- Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000;118:1264–1268 - PubMed
-
- Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study). Ophthalmic Epidemiol 2009;16:15–21 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical